Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition

Melanomas frequently harbor activating NRAS mutations leading to activation of MEK-ERK1/2 signaling; however, clinical efficacy of inhibitors to this pathway are limited by resistance. Tumors re-wire metabolic pathways in response to stress signals such as targeted inhibitors and drug resistance, bu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Invest Dermatol
Egile Nagusiak: Nguyen, Mai Q., Teh, Jessica L.F., Purwin, Timothy J., Chervoneva, Inna, Davies, Michael A., Nathanson, Katherine L., Cheng, Phil F., Levesque, Mitchell P., Dummer, Reinhard, Aplin, Andrew E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7606255/
https://ncbi.nlm.nih.gov/pubmed/32389536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jid.2020.02.047
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak